# US 2001/0056189 A1 · Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0056189 A1
- Document ID: US20010056189A1
- Status: Published application
- Kind: A1
- Application number: 09/878,538
- Filed: 2001-06-11
- Published: 2001-12-27
- Earliest claimed: 1998-09-14
- Assignees: Pharmacia Corporation
- Inventors: John J. Talley; James A. Sikorski; Matthew J. Graneto; Jeffrey S. Carter; Bryan H. Norma; Balekudru Devadas; Hwang-Fun Lu
- Web page: https://patentgrep.com/patent/US20010056189A1

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- B60G 17/018: characterised by the use of a specific signal treatment or control method
- B64C 27/001: {Vibration damping devices}
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- B60G 2400/102: vertical
- B60G 2400/206: Body oscillation speed; Body vibration frequency
- B60G 2400/25: Stroke; Height; Displacement
- B60G 2400/60: Load
- B60G 2400/91: Frequency
- B64C 2027/004: {using actuators, e.g. active systems}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- B60G: VEHICLE SUSPENSION ARRANGEMENTS (air-cushion vehicles B60V; {cycle suspensions B62K25/00})
- B64C: AEROPLANES; HELICOPTERS

## Abstract

This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.

## Claims

### Claim 1

A compound of Formula II
35
wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl; wherein A is optionally substituted with a radical selected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl; wherein Y is selected from lower alkyl, lower alkenyl and lower alkynyl; wherein R1 is selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylmino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R2 is selected from lower alkyl and amino; and wherein R6 is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl; provided R2 is amino when A is pyrazolyl; or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

Compound of claim 1 wherein A is selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl, wherein A is optionally substituted with a radical selected from formyl, fluoro, chloro, bromo, methyl, trifluoromethyl, oxo, cyano, carboxyl, methoxy, aminocarbonyl, methoxycarbonyl, ethoxycarbonyl, acetyl, carboxypropyl, and hydroxymethyl; wherein Y is a radical selected from methyl, ethyl, isopropyl, propyl, butyl, propenyl, butenyl, propynyl and butynyl; wherein R1 is selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, and phenyl, where R1 is optionally substituted at a substitutable position with one or more radicals selected from methyl, trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy, methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R2 is methyl or amino; and wherein R5 is selected from hydrido, methyl, and phenyl; or a pharmaceutically-acceptable salt thereof.

### Claim 3 (depends on 1)

A compound according to claim 1 selected from
[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-ethanamide;
4-[[4-aminosulfonyl)phenyl]-5-(3,4-dichlorophenyl)-N-hydroxy-2-oxazolebutanamide; and
4-(4-fluorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl) phenyl]-2-oxazolpropanamide.

### Claim 4

A compound of Formula III
36
wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl isothiazolyl, isoxazolyl, pyrazolyl, cyc-lopentenyl, phenyl, and pyridyl; wherein A is optionally substituted with a radical selected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl; wherein Y is selected from lower alkyl, lower alkenyl and lower alkynyl; wherein R1 is selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R2 is selected from lower alkyl and amino; and wherein R5 is selected from hydrido and alkyl; or a pharmaceutically-acceptable salt thereof.

### Claim 5 (depends on 4)

Compound of claim 4 wherein A is selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl, wherein A is optionally substituted with a radical selected from formyl, fluoro, chloro, bromo, methyl, trifluoromethyl, oxo, cyano, carboxyl, methoxy, aminocarbonyl, methoxycarbonyl, ethoxycarbonyl, acetyl, carboxypropyl, and hydroxymethyl; wherein Y is selected from methyl, ethyl, isopropyl, propyl, butyl, propenyl, butenyl, propynyl and butynyl; wherein R1 is selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, and phenyl, where R1 is optionallv substituted at a substitutable position with one or more radicals selected from methyl, trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy, methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R2 is methyl or amino; and wherein R5 is selected from hydrido, and methyl; or a pharmaceutically-acceptable salt thereof.

### Claim 6 (depends on 4)

A compound according to claim 4 which is N′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising a therapeutically-effective amount of a compound of claim 1-6, or a pharmaceutically-acceptable salt thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

Use of a compound of claim 1-6, or a pharmaceutically-acceptable salt thereof for preparing a medica-ment for treating a condition benefited by the in-hibition of 5-lipoxygenase, cyclooxygenase-2 or both 5-lipoxygenase and cyclooxygenase-2.

### Claim 9 (depends on 8)

Use according to claim 8 wherein the condition is inflammation or an inflammation-associated disorder.

### Claim 10 (depends on 9)

Use according to claim 9 wherein the condition is inflammation.

### Claim 11 (depends on 9)

The method of claim 9 wherein the condition is an inflammation-associated disorder.

### Claim 12 (depends on 11)

The method of claim 11 wherein the inflammation-associated disorder is arthritis.

### Claim 13 (depends on 11)

The method of claim 11 wherein the inflammation-associated disorder is pain.

### Claim 14 (depends on 11)

The method of claim 11 wherein the inflammation-associated disorder is fever.
